Citius Oncology Reports Fiscal Q3 2026 Results, LYMPHIR® Sales Progress

Citius Oncology, Inc. has announced its financial results for the third quarter of fiscal year 2026, reporting $7.1 million in revenue for the first nine months of the fiscal year. The company attributes this revenue to the ongoing progress of its LYMPHIR® product launch and strong institutional demand.

According to Citius Oncology, the total number of LYMPHIR® vials ordered and the number of institutions ordering the product have seen significant growth since its launch. A total of 44 institutions have placed orders for LYMPHIR®.

The company did not provide further details on future growth strategies or additional product pipeline developments in its press release. Citius Oncology is currently focused on securing licensing agreements and expanding the availability of LYMPHIR® within the U.S. market.

Further financial details are available on the company's investor relations website and through its filings with the U.S. Securities and Exchange Commission (SEC).